Navigation Links
PPTA Launches New Educational Website on Donating Plasma

ANNAPOLIS, Md., Sept. 19 /PRNewswire/ -- Today, more people can learn about the life-saving benefits of plasma donation through the website, Produced by the Plasma Protein Therapeutics Association (PPTA), this new educational website features information on plasma donation, how it helps patients with chronic, life-threatening diseases, and will help users easily find their local source plasma donation center.

PPTA designed this informative site in an effort to heighten public awareness of the importance of donating plasma. is the only industry-wide web site that seeks to explain and clarify the plasma donation process.

Plasma, the largest blood component, is the starting material for a wide-range of life-saving medicines used to treat life-threatening, rare, chronic, and often genetic diseases and disorders such as hemophilia, primary immunodeficiencies, alpha-1 antitrypsin deficiency and neurological and autoimmune disorders. In addition, plasma protein therapies are used to treat medical conditions such as shock, trauma and burns.

"A major goal of PPTA is to provide information to potential and current plasma donors that stresses the need for their donation, which is critical in helping to save countless lives," said PPTA President Jan M. Bult.

The site will contain up-to-the minute information about plasma donation, including donor eligibility and health, frequently asked questions, and the time and commitment required to donate plasma," Bult said. "We hope the site will be a resource for those interested in donating plasma and who want to learn more about the patients who are helped everyday by someone who gives plasma. With hundreds of thousands of people throughout the world depending on plasma-derived therapies, this new site should be valuable to those who are curious about ways in which they can become an essential part of saving someone's life." offers information regarding the diseases and disorders treated with plasma protein therapies, differences in blood and plasma collection, video segments offering real-life interviews with patients, plasma donors and physicians, and links to patient group organizations and other online resources.

To view the new website, please go to For more information please contact Kara Flynn at (443) 458-4669 or Kym H. Kilbourne at (443) 458-4682.

ABOUT PPTA: The Plasma Protein Therapeutics Association (PPTA) is the trade association and standard setting organization for the world's major producers of plasma-derived and recombinant analog therapies (collectively, "plasma therapies"). These therapies are used by more than 1 million people worldwide each year to treat a variety of diseases and serious medical conditions. PPTA members produce over 80 percent of the plasma therapies for the United States market and more than 60 percent worldwide. Some of the critical therapies produced by PPTA members include: blood clotting factors for people with hemophilia, intravenous immune globulin used to prevent infections in people with immune deficiencies and other serious conditions, and alpha-1 proteinase inhibitor used to treat people with alpha-1-antitrypsin deficiency, also known as genetic emphysema.

SOURCE Plasma Protein Therapeutics Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Drumlin Security Launches Ground-breaking Low Cost PDF Publishing Service
2. USHEALTH Group Launches Marketing Program for Two Health Insurance Plans Targeting Latino Residents in Florida
3. California Dental Association Foundation Launches New Dental Risk Assessment Campaign
4. Lumension Security Launches Podcast On Application Whitelisting: Keep The Bad Guys Out - Let The Good Guys In
5. Launches a Dynamic Web-Based Series of CME Certified Activities Entitled: Recognizing and Managing Diseases of The Leg: A Self-Study Program
6. National Health Plan Collaborative Launches Online Toolkit to Assist Health Plans in Reducing Disparities
7. NIH launches unique effort to advance study of urologic chronic pelvic pain disorders
8. US Oncology Launches New Services Division: Innovent Oncology
9. Launches HealthDecision '08: Obama and McCain on Health Care
10. Satyam Launches Comprehensive, Mobile Healthcare Program for Rural Indians
11. Cleveland Clinic Launches Fully Dedicated International Comprehensive Critical Care Program
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... for the care management and population health arenas, is pleased to announce that ... cost containment services, has successfully implemented the ACUITY Complete Care™ Management to back ...
(Date:12/1/2015)... GA (PRWEB) , ... December 01, 2015 , ... ... supports SACC-GA and SACC-USA through membership and leadership since 2008. Gary ... Chair for SACC-USA . Gary has spent a significant amount of time ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash Moradzadeh ... Man for 2015. , Angeleno Magazine is a division of Modern Luxury, ... 1994, Modern Luxury includes more than 50 magazine titles across 15 major markets. ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced today that it has officially launched a sleek, mobile-ready and user-centric redesigned ... his company’s new website clearly outlines the benefits that its SEO services provide ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 2015 Breg, Inc ., a premier ... that it has been awarded three contracts by Novation, ... Novation will have access to improved pricing for Breg,s ... soft goods dedicated to advancing orthopedic care.  ... U.S. population, rising prevalence of chronic conditions and the ...
(Date:12/1/2015)... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... has always been a country of choice for global multi-center ... Europe in 2015 were tested in phase II-III clinical ... has always been a country of choice for global multi-center phase III ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: